-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Traditional Chinese medicine has the advantages of stable nature, exact curative effect, relatively small toxic and side effects, and convenient taking, carrying, and storage.
It is a great creation of the Chinese nation and a treasure of ancient science in China.
The progress of world civilization has had a positive impact
.
It is understood that in recent years, multinational pharmaceutical companies have also begun to gradually set foot in the traditional Chinese medicine industry
.
Such as AstraZeneca, SK, Sanofi, Boehringer Ingelheim,
etc.
Among them, AstraZeneca’s innovation base focusing on traditional Chinese medicine has recently officially settled in Chengdu
.
It is reported that this is another important attempt in the traditional Chinese medicine industry after AstraZeneca and Luye Group reached the promotion cooperation of Xuezhikang
.
According to public information, the base will feature the modernized industry of traditional Chinese medicine, relying on academicians and experts to drive scientific research transformation and industrial development, and build a one-stop Chinese medicine incubation industry empowerment platform in the west, including new R&D institutions centered on academicians and experts, Modern and innovative Chinese medicine industry service platform, one-stop Chinese medicine clinical research and development transformation platform and Chinese medicine modern business platform
.
AstraZeneca said that the company will further lay out the incubation of key Chinese medicine varieties, and plans to introduce more high-quality Chinese patent medicines in the therapeutic areas that AstraZeneca is deeply cultivating, such as heart failure, stroke, and chronic kidney disease
.
In addition, as early as 2014, German pharmaceutical company Boehringer Ingelheim signed a three-year contract with GPHL to jointly promote a Chinese medicine product under GPHL
.
Foreign pharmaceutical companies began to enter the Chinese medicine product marketing market
.
It is reported that the product of the cooperation between the two parties is "Children's Qixing Tea Syrup", which is produced by Guangzhou Pangaoshou Pharmaceutical Co.
, Ltd.
, and the indication is Dingjing and stagnation.
, disturbed sleep at night, is an over-the-counter drug
.
Boehringer Ingelheim said at the time that it chose this drug for cooperation because it was optimistic about the preference of the domestic market for traditional Chinese medicine and children's medicine
.
For example, Sanofi has cooperated with China Resources Sanjiu to establish Sanjiu Sanofi.
It is reported that China Resources Sanjiu’s dominant products in the past were mainly cold medicines and proprietary Chinese medicines.
Since 2017, it has started to deploy in pediatrics, orthopedics, gynecology, hepatobiliary and other professional markets.
.
After the cooperation with Sanofi, Sanofi "Good Baby" will integrate with the existing pediatric brands of China Resources Sanjiu
.
Analysts said that in recent years, China's support for traditional Chinese medicine has continued to increase, and the traditional Chinese medicine market has great potential, which is attractive to multinational pharmaceutical companies to a certain extent
.
Especially since the promulgation of the "Chinese Medicine Law", Chinese medicine products enjoy certain policy dividends in the market competition
.
Not only that, in recent years, the release of the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" and the issuance of the "14th Five-Year Plan" for the development of traditional Chinese medicine have also provided policy encouragement for the development of traditional Chinese medicine
.
Favorable policies for traditional Chinese medicine are frequently issued, which to a certain extent attracts multinational pharmaceutical companies to enter the traditional Chinese medicine industry.
development
.
For example, AstraZeneca stated that the cooperation with Chengdu High-tech Zone to build a Chinese medicine innovation industry base will help AstraZeneca focus on the modernization and innovative development of Chinese medicine, and promote international exchange of experience
.
However, it is worth noting that the development of the Chinese medicine industry by multinational pharmaceutical companies still needs to face competition with local Chinese medicine companies.
Therefore, it is very important to choose appropriate products
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
It is a great creation of the Chinese nation and a treasure of ancient science in China.
The progress of world civilization has had a positive impact
.
It is understood that in recent years, multinational pharmaceutical companies have also begun to gradually set foot in the traditional Chinese medicine industry
.
Such as AstraZeneca, SK, Sanofi, Boehringer Ingelheim,
etc.
Among them, AstraZeneca’s innovation base focusing on traditional Chinese medicine has recently officially settled in Chengdu
.
It is reported that this is another important attempt in the traditional Chinese medicine industry after AstraZeneca and Luye Group reached the promotion cooperation of Xuezhikang
.
According to public information, the base will feature the modernized industry of traditional Chinese medicine, relying on academicians and experts to drive scientific research transformation and industrial development, and build a one-stop Chinese medicine incubation industry empowerment platform in the west, including new R&D institutions centered on academicians and experts, Modern and innovative Chinese medicine industry service platform, one-stop Chinese medicine clinical research and development transformation platform and Chinese medicine modern business platform
.
AstraZeneca said that the company will further lay out the incubation of key Chinese medicine varieties, and plans to introduce more high-quality Chinese patent medicines in the therapeutic areas that AstraZeneca is deeply cultivating, such as heart failure, stroke, and chronic kidney disease
.
In addition, as early as 2014, German pharmaceutical company Boehringer Ingelheim signed a three-year contract with GPHL to jointly promote a Chinese medicine product under GPHL
.
Foreign pharmaceutical companies began to enter the Chinese medicine product marketing market
.
It is reported that the product of the cooperation between the two parties is "Children's Qixing Tea Syrup", which is produced by Guangzhou Pangaoshou Pharmaceutical Co.
, Ltd.
, and the indication is Dingjing and stagnation.
, disturbed sleep at night, is an over-the-counter drug
.
Boehringer Ingelheim said at the time that it chose this drug for cooperation because it was optimistic about the preference of the domestic market for traditional Chinese medicine and children's medicine
.
For example, Sanofi has cooperated with China Resources Sanjiu to establish Sanjiu Sanofi.
It is reported that China Resources Sanjiu’s dominant products in the past were mainly cold medicines and proprietary Chinese medicines.
Since 2017, it has started to deploy in pediatrics, orthopedics, gynecology, hepatobiliary and other professional markets.
.
After the cooperation with Sanofi, Sanofi "Good Baby" will integrate with the existing pediatric brands of China Resources Sanjiu
.
Analysts said that in recent years, China's support for traditional Chinese medicine has continued to increase, and the traditional Chinese medicine market has great potential, which is attractive to multinational pharmaceutical companies to a certain extent
.
Especially since the promulgation of the "Chinese Medicine Law", Chinese medicine products enjoy certain policy dividends in the market competition
.
Not only that, in recent years, the release of the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" and the issuance of the "14th Five-Year Plan" for the development of traditional Chinese medicine have also provided policy encouragement for the development of traditional Chinese medicine
.
Favorable policies for traditional Chinese medicine are frequently issued, which to a certain extent attracts multinational pharmaceutical companies to enter the traditional Chinese medicine industry.
development
.
For example, AstraZeneca stated that the cooperation with Chengdu High-tech Zone to build a Chinese medicine innovation industry base will help AstraZeneca focus on the modernization and innovative development of Chinese medicine, and promote international exchange of experience
.
However, it is worth noting that the development of the Chinese medicine industry by multinational pharmaceutical companies still needs to face competition with local Chinese medicine companies.
Therefore, it is very important to choose appropriate products
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
